Neopharma has entered into a partnership with global pharma giant – Pfizer to locally manufacture selected pharmaceutical products in the UAE, in an effort to meet the unmet needs of patients in the region.
In partnership with Pfizer, Neopharma will start with a couple of cardiovascular medicines related to hypertension and heart diseases, and will later move on to anti-inflammatory, pain management, women’s health and anti-infective drugs.
Neopharma has a robust formulation, research and development team, world-class environment health and safety standards and is open to investing in the latest technology. It has a strong local market presence with more than 100 products with exports to Middle East, Africa and CIS.
The partnership with Pfizer will enable local production of Pfizer’s products that will dramatically reduce the trans-Atlantic and European supply chain timelines. It will also provide insulation against currency fluctuations and completely minimise stock out situations and ensure adequate product availability of chronic medication at all times.
The medicines will be produced at Neopharma’s Mussafah factory, and will be available in the UAE next year. These will eventually be rolled out in the rest of the Gulf countries. Neopharma’s overseas markets include Saudi Arabia, Oman, Qatar, Kuwait, Kenya and Afghanistan.
This partnership for research, drug development, manufacturing and distribution of Pfizer’s leading global therapies by Neopharma will allow Abu Dhabi to emerge as a hub for manufacturing and exporting Pfizer’s leading products in the region.